UPDATE 1-Indevus gets non-approvable letter for cancer therapy
(Recasts, adds share movement)
Dec 19 (Reuters) - Indevus Pharmaceuticals Inc IDEV.O said U.S. health regulators declined to approve its bladder cancer therapy, Valstar, sending shares tumbling more than 51 percent in late electronic trade to a new year-low.
Valstar was withdrawn from the market in 2002 due to impurities in the original formulation but the company said those issues have since been resolved.
The biopharmaceutical company said it received a non-approvable letter from the U.S. Food and Drug Administration related to the therapy's chemistry, manufacturing and controls New Drug Application supplement submitted in May.
In a statement, the company said during a recent pre-approval inspection by the FDA of the company's third-party manufacturing plant for Valstar, some deficiencies were identified.
The company did not disclose where the facility was located but said upon resolution, which it expects within several months, it will respond to the FDA and request re-inspection of the facility.
Shares of the company fell to $3.50 in late electronic trade, after closing at $7.16 on the Nasdaq. (Reporting by Swagata Gupta in Bangalore; Editing by Jarshad Kakkrakandy, Bernard Orr)
- Malaysian plane presumed crashed; questions over false IDs |
- CORRECTED-UPDATE 4-Malaysia Airlines plane crashes in South China Sea with 239 people aboard - report
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Libya threatens to bomb North Korean tanker if it ships oil from rebel port